AI Summary & Key Takeaways
AI InsightConclusion: Our study results demonstrated that serum IMA levels in the patients with ISSNHL did not differ from the control group.
📌 3 Key Takeaways
Abstract
Objectives: This study aims to investigate whether serum levels of ischemia-modified albumin IMA are associated with idiopathic sudden sensorineural hearing loss ISSNHL . Patients and Methods: Between December 2015 and June 2017, a total of 17 patients 9 males, 8 females; mean age 49.4±18.0 years; range, 24 to 88 years with ISSNHL and 24 age- and sex-matched healthy individuals 12 males, 12 females; mean age 44.5±13.3 years; range, 30 to 81 years as the control group were included in the study. All patients underwent audiometric examination at the time of admission immediately before the beginning of the treatment and weekly after treatment initiation until one month using the Interacoustics AC40 audiometer. Serum IMA levels were evaluated using blood samples from the antecubital vein of both patient and control groups. The samples were centrifuged to separate the serum from the cells. Albumin cobalt binding test was used for IMA measurement. Results: The mean IMA level was 0.374±0.081 absorbance units ABSU range, 0.205 to 0.536 in the study group at the time of diagnosis, 0.358±0.051 ABSU range, 0.297 to 0.466 in the post-treatment period, at least four weeks after onset, and 0.358±0.053 ABSU range, 0.281 to 0.434 in the control group. There was no statistically significant difference between the patient and control groups. The IMA levels of the patients with ISSNHL in the post-treatment period were lower than the onset of illness, although this difference was not statically significant 0.440 . Conclusion: Our study results demonstrated that serum IMA levels in the patients with ISSNHL did not differ from the control group.